Indian generic pharmaceutical trading
WHO-GMP and PIC/S certified supply network
Registered in Southeast Asia, the Caucasus and Central Asia
We work out what a market already registers, who supplies it today, and where the gaps sit. You get a filing order: the molecules to register first, and the dossier route behind each.
Therapy areas
Every molecule here has technical documentation held with the plant. Name the market and compilation to your authority's format begins.
View full portfolio →Across eleven published therapy areas and five dosage forms
Myanmar, Georgia, Turkmenistan, Tajikistan
Cleared with the drug authorities of the four active export markets
One Star Export House, Ministry of Commerce, India
How we work
The analysis runs before any shortlist goes out, so the conversation opens on molecules the market can register.
The same analysis sets the order we file our own dossiers in.
Manufacturing
Immediate and extended-release formulations across cardiovascular, diabetes, CNS and anti-infectives. Full ER and MR capability, including sustained-release combinations such as Pregabalin SR with Methylcobalamin and Divalproex Sodium ER. Dispersible tablets and dry syrups included.
Small-volume parenterals across the anti-infective spectrum: cephalosporins, carbapenems, reserve-class antibiotics, antifungals and corticosteroids. Lyophilised and liquid formats. Sterile manufacturing to BP and USP standards.
Sterile large-volume parenterals. Sodium chloride, dextrose, metronidazole, levofloxacin, paracetamol, and mannitol infusions. Glass and plastic containers. Terminally sterilised to WHO-GMP standard.
Large-volume parenterals require dedicated lines, separate from small-volume sterile filling. 12 molecules in the range, and the capability that opens institutional and hospital accounts.
Pressurised metered-dose inhalers, aqueous nasal sprays and sterile ophthalmic drops. MDI manufacture requires pressurised filling capability separate from standard sterile injectable lines. The ophthalmic range includes preservative-free presentations and combination antibiotic-steroid drops.
47 metered-dose inhalers, 30 nasal sprays and 177 ophthalmic presentations, together the 254 molecules on this card.
Full dosage form breakdown under Capabilities.
Markets
Each one was filed with the authority of the market it covers. We hold nothing yet in the Middle East or Africa, which is where the next filings go.
Every new supply relationship starts the same way, whether or not Aravis is already registered in the market. Request a portfolio analysis.
Tell us the market and what you stock.